Literature DB >> 7181477

Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acid.

A Iravani, G A Richard.   

Abstract

A 10-day course of amoxicillin (250 mg)-potassium clavulanate (125 mg) was administered three times daily to 116 female college students with urinary tract infections. All of the bacterial isolates from these patients were susceptible to amoxicillin-potassium clavulanate in vitro; only 81.0% were susceptible to amoxicillin alone. Evaluations at 1 week after completion of this course showed that clinical and bacteriological cures had been achieved in 96.9% of those who completed therapy. Cures were sustained in 85.6% of the patients examined at 4 weeks after the end of therapy. Therapeutic responses were comparable, irrespective of the results of antibody-coated bacteria tests. All strains of Enterobacteriaceae isolated from the rectal and urogenital sites at 1 week after therapy were susceptible to amoxicillin-potassium clavulanate. The proportion of fecal Escherichia coli resistant to amoxicillin alone increased from 13.3% before therapy to 35.6% at 1 week after therapy. Adverse drug reactions consisted of gastrointestinal symptoms (9.8%) and rashes (4.1%). Sixteen patients (14.2%) developed symptomatic candida vaginitis by 1 week after therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7181477      PMCID: PMC183812          DOI: 10.1128/AAC.22.4.672

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Note on an exact treatment of contingency, goodness of fit and other problems of significance.

Authors:  G H FREEMAN; J H HALTON
Journal:  Biometrika       Date:  1951-06       Impact factor: 2.445

Review 2.  Ampicillin.

Authors:  D M Bear; M Turck; R G Petersdorf
Journal:  Med Clin North Am       Date:  1970-09       Impact factor: 5.456

3.  A ten-year study of bacteriuria in schoolgirls: final report of bacteriologic, urologic, and epidemiologic findings.

Authors:  C M Kunin
Journal:  J Infect Dis       Date:  1970-11       Impact factor: 5.226

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

6.  Urinary tract infection caused by Staphylococcus saprophyticus.

Authors:  P A Jordan; A Iravani; G A Richard; H Baer
Journal:  J Infect Dis       Date:  1980-10       Impact factor: 5.226

7.  Effect of stay in hospital and oral chemotherapy on the antibiotic sensitivity of bowel coliforms.

Authors:  E J Shaw; N Datta; G Jones; F M Marr; W J Froud
Journal:  J Hyg (Lond)       Date:  1973-09

8.  Combined antibacterial activity of amoxicillin with clavulanic acid against ampicillin-resistant strains.

Authors:  M Matsuura; H Nakazawa; T Hashimoto; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  Bacampicillin vs. amoxicillin for treatment of acute infections of the urinary tract.

Authors:  G A Richard; A Iravani; J L LeFrock; W Mogabgab
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

10.  Treatment of uncomplicated urinary tract infections with trimethoprim versus sulfisoxazole, with special reference to antibody-coated bacteria and fecal flora.

Authors:  A Iravani; G A Richard; H Baer
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

View more
  14 in total

1.  Oral antibiotic therapy for acute pyelonephritis: a methodologic review of the literature.

Authors:  A G Pinson; J T Philbrick; G H Lindbeck; J B Schorling
Journal:  J Gen Intern Med       Date:  1992 Sep-Oct       Impact factor: 5.128

2.  Comparative study of cephradine and amoxicillin-clavulanate in the treatment of recurrent urinary tract infections.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

3.  Pharmacokinetic study of a paediatric formulation of amoxycillin and clavulanic acid in children.

Authors:  C H van Niekerk; J van den Ende; H K Hundt; E A Louw
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

Review 5.  Human immunodeficiency virus (HIV) infection. Does it increase susceptibility to adverse drug reactions?

Authors:  G E Harb; M A Jacobson
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

6.  Loracarbef versus cefaclor in the treatment of urinary tract infections in women.

Authors:  A Iravani
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

7.  Amoxicillin-clavulanic acid versus cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora.

Authors:  A Iravani; G A Richard
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

8.  Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children.

Authors:  G R Fleisher; C M Wilmott; J M Campos
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

9.  In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits.

Authors:  P C Fuchs; A L Barry; C Thornsberry; T L Gavan; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

10.  Prospective comparison of amoxicillin-clavulanic acid and cefaclor in treatment of uncomplicated urinary tract infections.

Authors:  M J Gurwith; G E Stein; D Gurwith
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.